Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m6A modification of LINC01579 and suppressing IL-17/NF-κB signaling

Background: A-dependent epigenetic mechanisms remains unclear. Objective: A modification. Methods: A levels were quantified by MeRIP-qPCR. Inflammation and pathway activation were assessed via immunofluorescence, Western blot, and enzyme-linked immunosorbent assay (ELISA). RNA stability was evaluated using actinomycin D assays, while cell migration was measured by scratch assays. Bone destruction was analyzed using micro-CT and histological staining. Additionally, an IL-17 pathway inhibitor (AIN457) and agonist (SR0987) were employed to validate pathway involvement. Results: , XFC ameliorated joint inflammation, bone erosion, and joint space narrowing in PGIA mice. Conclusion: XFC alleviates AS progression by inhibiting YTHDC1-mediated m6A modification of LINC01579, which prevents its degradation and subsequently dampens IL-17/NF-κB pathway activation. These findings highlight a potential epigenetic mechanism underlying the therapeutic effects of XFC in AS.